Phelps, R., Winston, J. A., Wynn, D., Habek, M., Hartung, H. P., Havrdová, E. K. ... Coles, A. J. (2019). Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis. Multiple Sclerosis Journal, 25. (9), 1273-1288. doi: 10.1177/1352458519841829
Phelps, Richard, et al. "Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis." Multiple Sclerosis Journal, vol. 25, no. 9, 2019, pp. 1273-1288. https://doi.org/10.1177/1352458519841829
Phelps, Richard, Jonathan A Winston, Daniel Wynn, Mario Habek, Hans Peter Hartung, Eva Kubala Havrdová, Glen S Markowitz, et al. "Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis." Multiple Sclerosis Journal 25, no. 9 (2019): 1273-1288. https://doi.org/10.1177/1352458519841829
Phelps, R., et al. (2019) 'Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis', Multiple Sclerosis Journal, 25(9), pp. 1273-1288. doi: 10.1177/1352458519841829
Phelps R, Winston JA, Wynn D, Habek M, Hartung HP, Havrdová EK, and sur.. Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis. Multiple Sclerosis Journal [Internet]. 2019 August [cited 2024 December 23];25(9):1273-1288. doi: 10.1177/1352458519841829
R. Phelps, et al., "Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis", Multiple Sclerosis Journal, vol. 25, no. 9, pp. 1273-1288, August 2019. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:942822. [Accessed: 23 December 2024]